Transforming growth factor beta engages TACE/ADAM17 and ErbB3 to activate PI3K/Akt in HER2-overexpressing breast cancer and desensitizes cells to trastuzumab

被引：0
|
作者：
Wang, E. [1 ]
Xiang, B. [1 ]
Olivares, M. G. [1 ]
Chang, C. [1 ]
Arteaga, C. L. [1 ]
机构：
[1] Vanderbilt Univ, Nashville, TN USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：72S / 72S
页数：1
相关论文
共 50 条
  • [41] Hyperactivation of the PI3K-AKT Pathway Commonly Underlies Resistance to Trastuzumab in HER2 Amplified Breast Cancer
    Chandarlapaty, S.
    King, T.
    Sakr, R.
    Barbashina, V
    Arroyo, N.
    Morrogh, M.
    Wynveen, C.
    Shanu, M.
    Norton, L.
    Rosen, N.
    Hudis, C.
    CANCER RESEARCH, 2009, 69 (24) : 526S - 527S
  • [42] Divergent activation of AKT1 and AKT2 isoforms downstream of PI3K mutation impacts response of breast cancer cells to estradiol and PI3K inhibitors
    Nakshatri, Harikrishna
    Goswami, Chirayu
    Badve, Sunil
    Magnani, Luca
    Lupien, Mathieu
    Bhat-Nakshatri, Poornima
    CANCER RESEARCH, 2015, 75
  • [43] BMP9 inhibits the growth of breast cancer cells by downregulation of the PI3K/Akt signaling pathway
    Li, Shu
    Dai, Hongying
    He, Yong
    Peng, Shusheng
    Zhu, Tianjin
    Wu, Yang
    Li, Chenwei
    Wang, Ke
    ONCOLOGY REPORTS, 2018, 40 (03) : 1743 - 1751
  • [44] A Mechanistic Logic for Dual Targeting of HER2 and PI3K/AKT/mTOR Signaling in HER2 Amplified Breast Cancer
    Chandarlapaty, S.
    Rodrik-Outmezguine, V.
    Scaltriti, M. Maurizio
    Sakr, R.
    Will, M.
    Giri, D.
    Hudis, C.
    Baselga, J.
    King, T.
    Rosen, N.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 127 - 127
  • [45] Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
    She, Q.-B.
    Chandarlapaty, S.
    Ye, Q.
    Lobo, J.
    Haskell, K. M.
    Leander, K. R.
    DeFeo-Jones, D.
    Huber, H. E.
    Rosen, N.
    CANCER RESEARCH, 2009, 69 (02) : 222S - 222S
  • [46] Promotion of metastasis of ERBB2-positive breast cancer by mesenchymal stem cells via exosomes-mediated activation of ERBB2/ERBB3. PI3K/Akt singaling pathway
    Wu, Yating
    Chen, Li
    Cao, Yue
    Huang, Qinfeng
    Niu, Huimin
    Lai, Xiaofeng
    Zhao, Meng
    Yan, Huihui
    Lyu, Hui
    Liu, Bolin
    Zhang, Shenghang
    Wang, Shuiliang
    CANCER RESEARCH, 2024, 84 (06)
  • [47] Role of SALL4 in HER2+Breast Cancer Progression: Regulating PI3K/AKT Pathway
    Pattanayak, Birlipta
    Lameirinhas, Ana
    Torres-Ruiz, Sandra
    Burgues, Octavio
    Rovira, Ana
    Teresa Martinez, Maria
    Tapia, Marta
    Zazo, Sandra
    Albanell, Joan
    Rojo, Federico
    Bermejo, Begona
    Eroles, Pilar
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [48] A preclinical evaluation of the isoform-specific PI3K inhibitor in HER2+breast cancer models with resistance to trastuzumab
    De, Pradip
    Aske, Jennifer Carlson
    Dey, Nandini
    CANCER RESEARCH, 2022, 82 (04)
  • [49] P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer
    Dillon, L. M.
    Bean, J. R.
    Yang, W.
    Shee, K.
    Symonds, L. K.
    Balko, J. M.
    McDonald, W. H.
    Liu, S.
    Gonzalez-Angulo, A. M.
    Mills, G. B.
    Arteaga, C. L.
    Miller, T. W.
    ONCOGENE, 2015, 34 (30) : 3968 - 3976
  • [50] P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer
    L M Dillon
    J R Bean
    W Yang
    K Shee
    L K Symonds
    J M Balko
    W H McDonald
    S Liu
    A M Gonzalez-Angulo
    G B Mills
    C L Arteaga
    T W Miller
    Oncogene, 2015, 34 : 3968 - 3976
12345